论文部分内容阅读
目的观察灵芝孢子粉对戊四氮(PTZ)致痫大鼠脑组织HO-1、cAMP、cGMP和血液中NSE含量变化的影响,探讨癫痫的发病机制及灵芝孢子粉的干预作用。方法 10周龄Wistar雄性大鼠30只,体质量(200±20)g,随机分成3组,分别是灵芝孢子粉组11只、癫痫模型组11只和空白对照组8只。灵芝孢子粉组和癫痫模型组用亚惊厥剂量(35 mg/kg)戊四氮(PTZ)腹腔注射,1次/d,连续28 d,大鼠连续5次出现2级以上惊厥确定为到达点燃标准,空白对照组用同体积生理盐水腹腔注射,同时灵芝孢子粉组经灌胃给予灵芝孢子粉(150 mg/kg,灌胃前禁食6 h);癫痫模型组和空白对照组经灌胃给予同等体积的生理盐水。实验结束后断头取血,在低温条件下迅速取出大脑,测定各相关指标的变化。结果实验性癫痫大鼠模型制作成功,灵芝孢子粉组和癫痫组实验动物全部达到点燃标准。高倍视野(100×)下,癫痫模型组海马和皮质区HO-1阳性细胞数明显较空白对照组增多(P<0.01),灵芝孢子粉组HO-1阳性细胞数低于癫痫模型组(P<0.05)。癫痫模型组cAMP、cGMP含量较正常对照组均有明显增加(P<0.01),同时cAMP/cGMP比值减小(P<0.01);与对照组比较,灵芝孢子粉治疗组cAMP含量增加(P<0.01),而cGMP含量较癫痫模型组明显降低(P<0.01),同时cAMP/cGMP比值亦增加,与癫痫模型组比较差异就有显著性(P<0.01)。血液中NSE的含量癫痫模型组与空白对照组相比增多(P<0.01),而与癫痫模型组比较,灵芝孢子粉治疗组血液中NSE的含量下降(P<0.05)。结论灵芝孢子粉可以降低癫痫时脑组织HO-1的含量,调节cAMP/cGMP比值减轻神经系统的异常放电,减轻过量的HO-1对神经元的损伤作用,降低血液中NSE的含量。
Objective To observe the effects of Ganoderma lucidum spores on HO-1, cAMP, cGMP and NSE in blood in PTZ-induced epilepsy rats, and to explore the pathogenesis of epilepsy and the intervention effect of Ganoderma spore powder. Methods Thirty Wistar male rats aged 10 weeks, weighing 200 ± 20 g, were randomly divided into three groups, including 11 ganoderma lucidum spores powder group, 11 epilepsy model group and 8 blank control group. Ganoderma lucidum spore powder group and epilepsy model group were injected intraperitoneally with pentylenetetrazole (PTZ) at a dose of 35 mg / kg once a day for 28 consecutive days. Rats in each group received convulsions of more than 2 levels for 5 consecutive days, The standard and blank control groups were injected intraperitoneally with the same volume of normal saline. At the same time, the ganoderma lucidum spore powder group was given Ganoderma lucidum spore powder by intragastric administration (150 mg / kg, fasting for 6 h before gavage); the epilepsy model group and the blank control group were given gavage Give the same volume of saline. At the end of the experiment, blood was decapitated, and the brain was removed rapidly under the condition of low temperature, and the changes of the relevant indexes were measured. Results Experimental epilepsy rat model was successfully produced. The experimental animals of Ganoderma lucidum spore powder group and epilepsy group all achieved the ignition standard. The number of HO-1 positive cells in hippocampus and cortex of high-power field (100 ×) group was significantly higher than that of blank control group (P <0.01), and the number of HO-1 positive cells in fungus spore powder group was lower than that of epilepsy model group <0.05). Compared with the control group, the cAMP and cGMP contents in the model group increased significantly (P <0.01) and the cAMP / cGMP ratio decreased (P <0.01). Compared with the control group, the cAMP content in the Ganoderma spore powder treatment group increased (P < 0.01). The cGMP level in epilepsy model group was significantly lower than that in epilepsy model group (P <0.01), and the cAMP / cGMP ratio also increased at the same time. The difference was statistically significant (P <0.01). The content of NSE in blood increased in epilepsy model group compared with that in the blank control group (P <0.01). Compared with the epilepsy model group, the content of NSE in the blood of the Ganoderma lucidum spore powder treatment group decreased (P <0.05). Conclusion Ganoderma lucidum spores powder can reduce the content of HO-1 in brain tissue of epilepsy, and regulate the ratio of cAMP / cGMP to reduce the abnormal discharge of nervous system, reduce the damage of excessive HO-1 to neurons and decrease the content of NSE in blood.